Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Hillhouse backs Elpiscience's $35M round

Elizabeth S. Eaton
December 4, 2018 9:12 PM UTC

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round.

Elpiscience is stocking its oncology pipeline through a mix of business development and internal R&D using an in-house suite of immunological assays to gauge how compounds affect key parameters like T cell exhaustion, NK cell cytotoxicity and myeloid-derived suppressor cell (MDSC) activity (see "Brake for Gas")...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Elpiscience Biopharmaceuticals Inc.

Lilly Asia Ventures